GoodRx reported a solid finish to 2025, with revenue and adjusted EBITDA in line with guidance. The company is strategically repositioning itself with a focus on its Pharma Direct business as a key growth driver, aiming to return to growth beyond 2026 and enhance its role in the healthcare ecosystem.
Full Year 2025 revenue increased 1% to $796.9 million compared to $792.3 million in the prior year.
positivePharma direct revenue increased 41% year-over-year to $151.4 million, driven by expanded market penetration and consumer direct pricing.
positiveFull Year 2025 Adjusted EBITDA increased to $270.5 million from $260.2 million in the prior year, with Adjusted EBITDA Margin improving to 33.9% from 32.8%.
positiveNet income for Full Year 2025 was $30.4 million, a significant increase from $16.4 million in the prior year.
positivePrescription transactions revenue decreased 6% to $544.0 million, primarily driven by a decrease in Monthly Active Consumers due to changes in the retail pharmacy landscape and volume reduction in an integrated savings program.
negativeSubscription revenue decreased 3% to $83.8 million, primarily driven by a decrease in the number of subscription plans.
negativeNet cash provided by operating activities decreased to $167.9 million in 2025 from $183.9 million in 2024.
attentionFull Year 2026 revenue is projected to decrease between 6% and 2% to $750 - $780 million, indicating a continued revenue decline.
negativeMonthly Active Consumers (MACs) decreased to 5.3 million in Q4 2025 from 6.6 million in Q4 2024.
negativeMargin expansion indicates improving profitability and operational efficiency. Measured in basis points (bps): 100 bps = 1.0%.
| Segment | Current | Prior Yr | YoY | % Total |
|---|---|---|---|---|
Prescription transactions revenue | N/A | — | — | — |
Subscription revenue | N/A | — | — | — |
Pharma direct revenue | N/A | — | — | — |
Other revenue | N/A | — | — | — |
| Total Revenue | $0.00M | — | — | 100.0% |
Segment performance shows business unit health and growth drivers.
Forward-looking guidance is subject to change and does not constitute a guarantee. Actual results may differ materially from these estimates.
Delivered a strong finish to the year by executing across key priorities, expanding manufacturer partnerships, growing differentiated subscription offerings, and strengthening retail relationships.
Rebranded Pharma Manufacturer Solutions as Pharma Direct and are continuing to elevate it as a key growth driver, reflecting belief that self-pay and direct-to-consumer engagement will define the future of prescription access.
Confident that the actions being taken position the company to return to growth beyond 2026, expand its role across the healthcare ecosystem, and create meaningful long-term value.
Commentary excerpts from earnings call transcripts provide management's perspective on performance, strategy, and outlook. Always review full transcripts for complete context.
Operational metrics provide insight into business drivers and customer engagement beyond traditional financial measures.